Phase III MORNINGSKY study of direct-acting antiviral (AT-527) in outpatient treatment of Covid-19 begins

AT-527 targets SARS-CoV-2 ribonucleic acid polymerase (nsp12), a gene responsible for viral RNA replication and transcription, and it is anticipated that it will be effective against emerging strains of the virus. The trial will involve patients with mild or moderate Covid-19.

Source:

Biospace Inc.